Advertisement
News
Advertisement

Novo Nordisk to Invest $73m in Expansion of U.S. Manufacturing Facility

Mon, 10/04/2010 - 9:33am
Bio-Medicine.Org

PRINCETON, N.J., Oct. 4 /PRNewswire/ -- Novo Nordisk, a global healthcare company and leader in diabetes care, today announced a $73 million expansion of its Clayton, NC manufacturing facility to accommodate increased production capacity for the Company's insulin delivery devices.

The initial expansion will create 205 new jobs, including 85 in the Novo Nordisk Clayton facility, which currently produces a number of products, including the Levemir® FlexPen® (insulin detemir [rDNA origin] injection) and other products for the entire diabetes portfolio. Novo Nordisk currently has more than 420 employees in Clayton who oversee the full production process for six different diabetes treatment products, from formulation through packaging and distribution. The expansion will include the addition of two final assembly lines, two packing lines and building refurbishment.

"The investment to expand our Clayton facility is another example of our commitment to improving diabetes treatment options in the U.S. by ensuring patients have access to the latest advances in treatment," said Jerzy Gruhn, president of Novo Nordisk Inc. "Insulin delivery devices give people with diabetes a convenient way to manage their health and engage in a productive lifestyle. As patients in the U.S. continue to move from administering insulin with a conventional vial and syringe to using a pen device, Novo Nordisk will be prepared to meet growing market demand."

Novo Nordisk, which created the first insulin pen device in 1985, is a world leader in producing and delivering innovative insulin delivery systems. The company has been working with physicians and patients to demonstrate the many benefits of modern delivery devices over vials and syringes, including adherence, ease of use and dosing accuracy. Since their launch 25 years ago, devices have become the dominant form of insulin delivery in most markets outside the U.S. and are gaining share domestically.

Novo

'/>"/>

SOURCE

Topics

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading